Bolton (MA) , San Antonio (TX) (PRWEB) June 30, 2016
Intrinsic Imaging, an FDA audited, ISO 9001, 13485 and 22301 certified imaging core lab, announced today that it has been awarded a global Phase III clinical trial designed to investigate the safety and efficacy of a new treatment for Central Precocious Puberty (CPP).
With its team of 70 full-time board-certified, fellowship trained radiologists, Intrinsic Imaging has extensive experience in providing services in support of Phase I-IV Clinical Trials and Class I, II and III Medical Device Trials across all therapeutic areas and indications.
Intrinsic Imaging’s Musculoskeletal team consists of 12 fellowship trained radiologists with expertise in the full complement of joint and spine diseases. Intrinsic Imaging has a wealth of experience in the qualitative evaluation of musculoskeletal diseases utilizing various quantitative assessments criteria systems including examples such as Greulich and Pyle, Kellgren-Lawrence, OARSI, and WORMS.
Throughout this Phase III international trial, Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, radiological review and data management.
“The outcome of this important Phase III study will determine if this new treatment compares favorably with the current standard of care,” said Todd A. Joron, BSc., MBA, President & COO at Intrinsic Imaging. “Intrinsic Imaging is proud to provide our expertise in assessing if this new treatment can bring relief to children suffering from precocious puberty around the world.”
Central precocious puberty (CPP) is characterized by early pubertal changes, acceleration of growth velocity and rapid bone maturation that often result in reduced adult height.
About Intrinsic Imaging
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, 13485 and 22301 certified, medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than seventy board-certified, fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world.
For more information on this release or Intrinsic Imaging, please contact Craig Pennington at craig(dot)pennington(at)IntrinsicCRO(dot)com or visit our website at http://www.IntrinsicCRO.com.